Zusammenfassung
Die S3-Pankreaskarzinomleitlinie wurde im letzten Jahr aktualisiert. Neben der internistisch-onkologischen und Palliativtherapie standen die chirurgische Therapie und insbesondere die Pathologie im sog. Themenkomplex 3 zur Aktualisierung an. Die Neuerungen betreffen im Wesentlichen die histopathologische Aufarbeitung, die besonders im Hinblick auf den zirkumferenziellen Resektionsrand und die R-Klassifikation überarbeitet wurde. Weiterhin wird in den Empfehlungen festgelegt, welche Angaben ein vollständiger pathohistologischer Befund enthalten sollte. Insbesondere auf die Angabe der Lymphknotenratio wird abgehoben.
Abstract
The S3 guidelines for pancreatic cancer were revised in 2013. Besides the oncological and palliative therapy modalities and surgical therapy, the guidelines for pathologists in topic 3 were updated. The modifications essentially concern the histopathological assessment of surgical specimens and in particular the circumferential resection margin and the R classification. In addition, the current recommendations were amended by recommendations concerning the pathohistological records, which should include the lymph node ratio in the future.
This is a preview of subscription content, log in via an institution to check access.
Literatur
Leitlinienprogramm S3-Leitlinie Exokrines Pankreaskarzinom, Langversion 1.0, 2013, AWMF Registernummer: 032-010OL. http://leitlinienprogramm-onkologie.de/Leitlinien.7.0.html. Zugegeriffen: 12. Juni 2014. (Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF)
Belyaev O, Herzog T, Chromik AM et al (2006) Pankreaschirurgie – Der Chirurg als entscheidender Prognosefaktor. Gastroenterologe 1:34-42
Seelig MH, Janot M, Chromik AM et al (2009) Redo-surgery following curative resection of pancreatic carcinoma: the difference between true and suspected recurrence. Dig Surg 26:222–228
Jamieson NB, Foulis AK, Oien KA et al (2010) Positive mobilization margins alone do not influence survival following pancreatico-duodenectomy for pancreatic ductal adenocarcinoma. Ann Surg 251:1003–1010
Gaedcke J, Gunawan B, Grade M et al (2010) The mesopancreas is the primary site for R1 resection in pancreatic head cancer: relevance for clinical trials. Langenbecks Arch Surg 395:451–458
Vincent A, Herman J, Schulick R et al (2011) Pancreatic cancer. Lancet 378:607–620
Adler G, Seufferlein T, Bischoff SC et al (2007) S3-Guidelines „Exocrine pancreatic cancer“ 2007. Z Gastroenterol 45:487–523
Menon KV, Gomez D, Smith AM et al (2009) Impact of margin status on survival following pancreatoduodenectomy for cancer: the Leeds Pathology Protocol (LEEPP). HPB (Oxford) 11:18–24
Munding J, Uhl W, Tannapfel A (2011) R classification and pancreatic ductal adenocarcinoma – R 0 is R 0. Z Gastroenterol 49:1423–1427
Bosman FT, Carneiro F, Hruban RH (Hrsg) (2010) WHO classification of tumours of the digestive system. World Health Orgn
Reid MD, Bagci P, Adsay NV (2012) Histopathologic assessment of pancreatic cancer: does one size fit all? J Surg Oncol
Wittekind C, Meyer HJ (2010) TNM Klassifikation maligner Tumore. Wiley-Blackwell, Weinheim
Tannapfel A (2010) Pancreatic cancer. Molecular and surgical pathology. Pathologe 31(Suppl 2):225–228
Campbell F, Smith RA, Whelan P et al (2009) Classification of R1 resections for pancreatic cancer: the prognostic relevance of tumour involvement within 1 mm of a resection margin. Histopathology 55:277–283
Esposito I, Kleeff J, Bergmann F et al (2008) Most pancreatic cancer resections are R1 resections. Ann Surg Oncol 15:1651–1660
Janot MS, Kersting S, Belyaev O et al (2012) Can the new RCP R0/R1 classification predict the clinical outcome in ductal adenocarcinoma of the pancreatic head? Langenbecks Arch Surg
Raut CP, Tseng JF, Sun CC et al (2007) Impact of resection status on pattern of failure and survival after pancreaticoduodenectomy for pancreatic adenocarcinoma. Ann Surg 246:52–60
Verbeke CS (2008) Resection margins and R1 rates in pancreatic cancer – are we there yet? Histopathology 52:787–796
Verbeke CS, Knapp J, Gladhaug IP (2011) Tumour growth is more dispersed in pancreatic head cancers than in rectal cancer: implications for resection margin assessment. Histopathology 59:1111–1121
Chang DK, Johns AL, Merrett ND et al (2009) Margin clearance and outcome in resected pancreatic cancer. J Clin Oncol 27:2855–2862
Hartwig W, Hackert T, Hinz U et al (2011) Pancreatic cancer surgery in the new millennium: better prediction of outcome. Ann Surg 254:311–319
Wittekind C, Compton C, Quirke P et al (2009) A uniform residual tumor (R) classification: integration of the R classification and the circumferential margin status. Cancer 115:3483–3488
Fietkau R, Heinemann V, Oettle H et al (2010) New data on pancreatic cancer. Onkologie 33(Suppl 4):31–35
Seufferlein T, Adler G (2009) The S3 guideline exocrine pancreatic cancer. Med Klin (Munich) 104:869–874
Jones S, Zhang X, Parsons DW et al (2008) Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science 321:1801–1806
Costello E, Greenhalf W, Neoptolemos JP (2012) New biomarkers and targets in pancreatic cancer and their application to treatment. Nat Rev Gastroenterol Hepatol 9:435–444
Chatterjee D, Katz MH, Rashid A et al (2012) Histologic grading of the extent of residual carcinoma following neoadjuvant chemoradiation in pancreatic ductal adenocarcinoma: a predictor for patient outcome. Cancer 118:3182–3190
Einhaltung ethischer Richtlinien
Interessenkonflikt. J. Munding,·J. Lüttges, I. Esposito und A. Tannapfel geben an, dass kein Interessenkonflikt besteht.
Dieser Beitrag beinhaltet keine Studien an Menschen oder Tieren.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Munding, J., Lüttges, J., Esposito, I. et al. Update der S3-Leitlinie für das Pankreaskarzinom. Pathologe 35, 509–520 (2014). https://doi.org/10.1007/s00292-012-1712-7
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00292-012-1712-7